Oppenheimer cuts target to USD 1,038 for Argenx stock

Published on 10/14/2026 at 10:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.54 billion, above USD 1.45 billion consensus. Argenx stock stood at EUR 715.80 on October 14, 2026.

Analyst target and quarterly sales

Oppenheimer cut its target from USD 1,100.00 to USD 1,038.00 on October 12, 2026.
Second-quarter revenue reached USD 1.54 billion versus USD 1.45 billion consensus.
Argenx stock trades at EUR 715.80 at 10:03 a.m. CEST at Lang & Schwarz on October 14, 2026.

Schwarz-Weiß-Reportagefoto: Forscherin beugt sich konzentriert über ein Mikroskop im Immunologie-Labor, dramatisches Chiaroscuro-Licht, körnige Filmtextur — Argenx NL0010832176 Reportagefoto in Schwarz und Weiß zeigt Wissenschaftlerin bei der Autoimmun-Forschung am Mikroskop, Illustration mit AI erstellt.

Argenx (ISIN NL0010832176) was trading at EUR 715.80 at Lang & Schwarz on October 14, 2026 at 10:03 a.m. CEST. Oppenheimer cut its price target from USD 1,100.00 to USD 1,038.00 on October 12, 2026, according to MarketBeat.

Target cut follows strong sales

The revised target came after argenx posted second-quarter revenue of USD 1.54 billion against consensus of USD 1.45 billion. The same period produced diluted earnings per share of USD 7.32 versus a USD 5.86 consensus estimate, according to MarketBeat. Those figures give investors a useful counterweight to the lower valuation call.

What does the target cut mean?

Oppenheimer kept an outperform rating while lowering the target, making the change a valuation adjustment rather than a bearish rating shift. The company profile identifies argenx as a biotechnology group focused on therapies for autoimmune diseases, with VYVGART and VYVGART Hytrulo among its approved products.

Three events shaped the stock

On October 8, 2026, argenx said its Phase 2 FB102 study in celiac disease met its primary endpoint with a p-value of 0.0176, and the company planned to advance the program into Phase 3, according to argenx. On October 9, 2026, a report said the UNITY Phase 3 study in Sjogren disease was discontinued after an interim analysis found that it was unlikely to meet its primary endpoint, according to Zacks. On October 12, 2026, Oppenheimer lowered its target to USD 1,038.00 from USD 1,100.00 while retaining an outperform rating, according to MarketBeat.

Next reporting date is October 22

argenx is scheduled to report its next earnings on October 22, 2026, before the market opens, according to Equity Rank. That date will test whether the second-quarter sales pace and earnings strength can offset the clinical setback in Sjogren disease.

Stock price and valuation context

argenx stock was trading at EUR 715.80 at Lang & Schwarz on October 14, 2026 at 10:03 a.m. CEST. The primary Nasdaq listing was last quoted at USD 802.64 on October 13, 2026 at 4:00 p.m. ET, with a market capitalization of USD 50.5 billion and a 52-week range of USD 661.85 to USD 1,072.75. The figures put the upcoming report at the center of the next valuation test. The further course of trading is shown by the continuously updated real-time quote of Argenx stock.